WJTOG

AcronymDefinition
WJTOGWest Japan Thoracic Oncology Group
References in periodicals archive ?
These include IPASS (10), First-SIGNAL (35), WJTOG 3405 (36), NEJ002 (37), OPTIMAL (38), EURTAC (11), Lux-LUNG 3 (12), and Lux-LUNG 6 (39).
patients/drug] EGFR Platinum- P TKI doublet IPASS (10,33) 71.2% 47.3% <0.001 [437/gefitinib] NEJ002 (37) 73.7% 30.7% <0.001 [230/gefitinib] WJTOG 3405 (36) 62.1% 32.2% <0.001 [177/gefitinib] OPTIMAL (38) 83% 36% <0.001 [154/erlotinib] EURTAC (11) 58% 15% <0.001 [173/erlotinib] LUX-Lung 3 (12) 56% 23% 0.001 [345/afatinib] LUX-Lung 6 (39) 66.9% 23% <0.001 [366/afatinib] Trial (reference) PFS (months) [no.
(%) IPASS (9,74) Gefitinib versus 261/437 (59.7) paclitaxel/ carboplatin in nonsmokers or former light smokers with advanced NSCLC of adenocarcinoma histology (N = 1217) WJTOG Gefitinib versus 172/172 (100) 3405 (8) docetaxel/cisplatin in EGFR mutation- positive advanced or postoperatively recurring NSCLC (N = 177) North-East Gefitinib versus 228/228 (100) Japan paclitaxel/ Study carboplatin in Group EGFR mutation- Gefitinib positive advanced 002 trial (7) or postoperatively recurring NSCLC (N = 228) Results in EGFR Mutation-Positive Patients Active Objective Treatment Response Rates, Trial Arms No.